A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma

A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma

Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer (NSCLC) and extensive disease small-cell lung cancer (ED-SCLC). It has been repor...

Full description

Bibliographic Details
Main Authors: Satoshi Tanaka, Ryo Asakawa, Kiyohide Komuta, Satoshi Tanizaki, Tomohiro Kanai, Muneyoshi Kuroyama, Kohki Shimazu, Junji Uchida, Takayuki Yakushijin, Kiyonobu Ueno
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Immune checkpoint inhibitors (ICIs)
Combination immunochemotherapy
Immune-related adverse events (irAEs)
Hepatitis
Pancreatitis
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007120304809
Description
Summary:Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer (NSCLC) and extensive disease small-cell lung cancer (ED-SCLC). It has been reported various immune-related adverse events (irAEs). We herein report a 65-year-old man with NSCLC who developed hepatitis and pancreatitis simultaneously during the combination immunochemotherapy. In the treatment of hepatitis and pancreatitis, the clinical course was different. In this report, the importance of accurate diagnosis through detailed examination and treatment priority depending on the severity of the symptoms is indicated.
ISSN:2213-0071

Similar Items